Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Altimmune Inc (ALT)
NASDAQ:ALT
Altimmune (ALT) Stock Price & Analysis
2,585 Followers
ALT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.09 - $14.84
Previous Close$7.3
Volume2.02M
Average Volume (3M)4.67M
Market Cap
$517.54M
Enterprise Value$319.72M
Total Cash (Recent Filing)$197.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-4.4
Beta0.61
Next Earnings
May 09, 2024EPS Estimate
-$0.37Last Dividend Ex-Date
Feb 06, 2017Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding70,895,286
10 Day Avg. Volume2,923,237
30 Day Avg. Volume4,666,657
Standard Deviation0.56
R-Squared0.00037
Alpha0.10
Financial Highlights & Ratios
Price to Book (P/B)2.67
Price to Sales (P/S)13987.45
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue750.52
Enterprise Value/Gross Profit750.52
Enterprise Value/Ebitda-3.62
Forecast
1Y Price Target
$23.40Price Target Upside220.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Altimmune News
Bulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyPemvidutide demonstrates a competitive edge with its unique ability to preserve lean mass during weight loss, potentially enabling better long-term weight management and a favorable safety profile.
Financial StabilityAltimmune's robust financial position, highlighted by its substantial cash reserves, signals a strong foundation for continued development and potential commercialization of pemvidutide.
Strategic PartnershipsOngoing discussions for strategic partnerships suggest growing confidence in pemvidutide's future, underpinning its potential as a differentiated therapeutic candidate in the obesity and NASH markets.
Bears Say
Drug DevelopmentDiscontinued development of HepTcell immunotherapy due to insufficient overall response in Phase 2 trial.
Financial OutlookPrice target for Altimmune has been reduced from $15 to $8 due to ongoing market dynamics and future capital needs.
Safety And EfficacyHigh incidence of gastrointestinal adverse events, such as nausea, in Phase 2 trials could be a concern for pemvidutide's user acceptance.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALT FAQ
What was Altimmune Inc’s price range in the past 12 months?
Altimmune Inc lowest stock price was $2.09 and its highest was $14.84 in the past 12 months.
What is Altimmune Inc’s market cap?
Currently, no data Available
When is Altimmune Inc’s upcoming earnings report date?
Altimmune Inc’s upcoming earnings report date is May 09, 2024 which is today.
How were Altimmune Inc’s earnings last quarter?
Altimmune Inc released its earnings results on Mar 27, 2024. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.455 by -$0.085.
Is Altimmune Inc overvalued?
According to Wall Street analysts Altimmune Inc’s price is currently Undervalued.
Does Altimmune Inc pay dividends?
Altimmune Inc pays a Notavailable dividend of $873 which represents an annual dividend yield of N/A. See more information on Altimmune Inc dividends here
What is Altimmune Inc’s EPS estimate?
Altimmune Inc’s EPS estimate is -$0.37.
How many shares outstanding does Altimmune Inc have?
Altimmune Inc has 70,895,290 shares outstanding.
What happened to Altimmune Inc’s price movement after its last earnings report?
Altimmune Inc reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.455. Following the earnings report the stock price went up 2.775%.
Which hedge fund is a major shareholder of Altimmune Inc?
Among the largest hedge funds holding Altimmune Inc’s share is Ardsley Advisory Partners. It holds Altimmune Inc’s shares valued at 4M.
---
Altimmune Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.40 (220.55% Upside)
$23.40 (220.55% Upside)
Blogger Sentiment
Bullish
ALT Sentiment 98%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 706.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.58%
12-Months-Change
Fundamentals
Return on Equity
-46.63%
Trailing 12-Months
Asset Growth
1.79%
Trailing 12-Months
Company Description
Altimmune Inc
The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.
---
ALT Earnings Call
Q4 2024
0:00 / 0:00
---
ALT Stock 12 Month Forecast
Average Price Target
$23.40
▲(220.55% Upside)
Technical Analysis
Best Analysts Covering ALT
1 Year
1 Year Success Rate
14/33 ratings generated profit
1 Year Average Return
+6.58%
reiterated a buy rating last month
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 42.42% of your transactions generating a profit, with an average return of +6.58% per trade.
---